2023 No. 5

2023 No.5

Theme Issue: Cell Therapy for Liver Disease

Executive Chief Editor: WANG Guiqiang

Department of Infectious Diseases, Peking University First Hospital

Cover Content

Previous Issue | Next Issue

Select articles

Display Method:

Editorial

Application and prospect of cell therapy in clinical treatment of liver diseases

Guiqiang WANG

2023, 39(5): 1001-1003. DOI: 10.3969/j.issn.1001-5256.2023.05.001

Abstract(689)

HTML (141)

PDF (1914KB)(196)

Abstract:
Cell therapy is an emerging therapy different from traditional drug therapy, among which immune cells and mesenchymal stem cells are the two types of most promising cells in the treatment of liver diseases at present, and preliminary results have been achieved for their therapeutic effects. This art...

Discussions by Experts

Clinical research advances in mesenchymal stem cells for the treatment of autoimmune liver diseases

Wanwan SHI, Jiandan QIAN, Guiqiang WANG

2023, 39(5): 1004-1009. DOI: 10.3969/j.issn.1001-5256.2023.05.002

Abstract(817)

HTML (267)

PDF (1882KB)(161)

Abstract:
Due to limited options and modalities for the etiological treatment of autoimmune liver diseases, it is urgent to seek new therapeutic methods for liver autoimmune diseases. As the most common source of cells for stem cell therapy, mesenchymal stem cells (MSCs) play an important role in regulating i...

Clinical research advances in mesenchymal stem cells for the treatment of end-stage liver disease

Yu FENG, Junfeng CHEN, Bingliang LIN

2023, 39(5): 1010-1018. DOI: 10.3969/j.issn.1001-5256.2023.05.003

Abstract(745)

HTML (205)

PDF (1911KB)(156)

Abstract:
End-stage liver disease (ESLD) includes decompensated liver cirrhosis and liver failure, which usually have dangerous conditions and a poor prognosis. Liver transplantation is the only effective therapy for ESLD, but its clinical application is limited due to shortage of liver donors, immunological ...

Clinical research advances in chimeric antigen receptor T-cell therapy for primary liver cancer

Shuang LI, Zherui LIU, Qi ZHAO, Yinying LU

2023, 39(5): 1019-1029. DOI: 10.3969/j.issn.1001-5256.2023.05.004

Abstract(982)

HTML (536)

PDF (2322KB)(159)

Abstract:
Primary liver cancer (PLC) has the features of insidious onset and difficulties in early diagnosis, with limited and ineffective therapeutic options. Chimeric antigen receptor (CAR) T-cell therapy is a genetically modified T-cell therapy that recognizes tumor-specific antigens and activates T cells ...

Research advances in tumor-infiltrating lymphocytes in treatment of biliary tract cancer

Xueshuai WAN, Xiaobing XIE, Haitao ZHAO, Weiyue GU, Henghui ZHANG

2023, 39(5): 1030-1036. DOI: 10.3969/j.issn.1001-5256.2023.05.005

Abstract(668)

HTML (293)

PDF (1885KB)(124)

Abstract:
Tumor-infiltrating lymphocytes (TILs) are a heterogeneous subset of lymphocytes, mainly T cells, present in tumor parenchyma and stroma. After being digested and isolated from tumor tissue and then cultured in vitro for activation and multiplication, it can be infused back into the patient's body to...

Academic contention

Opinion on the definition of "occult hepatitis B virus infection"

Rongrong XUE, Xinru WANG, Li XIAO, Chengyuan LIU, Wei WANG, Hongtao XU, Jianchun XIAN

2023, 39(5): 1037-1040. DOI: 10.3969/j.issn.1001-5256.2023.05.006

Abstract(774)

HTML (140)

PDF (1843KB)(146)

Abstract:
The presence of replication-competent HBV DNA in the liver and/or serum of HBsAg-negative individuals is a sufficient and necessary condition for the diagnosis of occult hepatitis B virus infection (OBI). In recent years, Chinese scholars have proposed what is considered a more "rigorous" definition...

Guideline

Diagnosis and treatment guideline for Chinese Medicine on non-alcoholic steatohepatitis

Branch of Hepatobiliary Diseases, China Association of Chinese Medicine

2023, 39(5): 1041-1048. DOI: 10.3969/j.issn.1001-5256.2023.05.007

Abstract(1512)

HTML (371)

PDF (1893KB)(528)

Abstract:

A brief introduction of AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease in 2023

Wenjing NI, Jie LI, Jiangao FAN

2023, 39(5): 1049-1055. DOI: 10.3969/j.issn.1001-5256.2023.05.008

Abstract(1749)

HTML (722)

PDF (3058KB)(554)

Abstract:

Original Article_Viral Hepatitis

Seroepidemiological characteristics of hepatitis B virus among hospitalized patients aged 18 years or below in Henan Province of China

Wei LI, Yanhong KANG, Jiangfeng ZHANG, Hui YIN, Junping LIU, Yukui LI, Yi KANG

2023, 39(5): 1056-1060. DOI: 10.3969/j.issn.1001-5256.2023.05.009

Abstract(531)

HTML (106)

PDF (2003KB)(70)

Abstract:
Objective To investigate the current status of hepatitis B virus (HBV) infection among hospitalized patients aged 1-18 years, as well as the status of immunity after hepatitis B vaccination. Methods Related data were collected from the patients aged 1-18 years who were hospitalized in Henan Provinci...

Efficacy and safety of tenofovir alafenamide fumarate in treatment of chronic hepatitis B patients aged ≥60 years in Qingdao, China

Yuwen SONG, Lizhen CHEN, Wenwen JIN, Ning GENG, Yang ZHANG, Shuixian DU, Bentian ZHAO, Jianping DUAN, Yong ZHOU, Chunhua BI, Lei MA, Xinxin HU, Jihong ZHANG, Jiantao SUN, Jie TAN, Yongning XIN

2023, 39(5): 1061-1069. DOI: 10.3969/j.issn.1001-5256.2023.05.010

Abstract(973)

HTML (301)

PDF (2730KB)(130)

Abstract:
Objective To investigate the application value of tenofovir alafenamide fumarate (TAF) in elderly patients with chronic hepatitis B (CHB) and its influence on bones and kidneys. Methods A total of 36 CHB patients, aged ≥60 years, who received TAF antiviral therapy in Qingdao Municipal Hospital, The ...

Value of combined baseline serum HBV markers in predicting HBeAg seroconversion in chronic hepatitis B patients treated by nucleos(t)ide analogues

Yang WANG, Hao LIAO, Zhongping DENG, Jing ZHAO, Dandan BIAN, Yan REN, Yingying JIANG, Shuang LIU, Yu CHEN, Fengmin LU, Zhongping DUAN, Sujun ZHENG

2023, 39(5): 1070-1075. DOI: 10.3969/j.issn.1001-5256.2023.05.011

Abstract(509)

HTML (126)

PDF (1877KB)(109)

Abstract:
Objective To investigate the ability of combined baseline serum markers, i.e., HBV DNA, HBV RNA, HBsAg, and HBcrAg, to predict HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B (CHB) treated by nucleos(t)ide analogues. Methods A retrospective analysis was performed for 83 HBeA...

Epidemiological situation of hepatitis D in the gathering area of Mongolian population in Inner Mongolia Autonomous Region of China

Chunshan FU, Xiaomei FENG, Xiumei CHI, Jun ZI, Junqi NIU, Zhuancai ZHANG

2023, 39(5): 1076-1080. DOI: 10.3969/j.issn.1001-5256.2023.05.012

Abstract(491)

HTML (128)

PDF (2140KB)(70)

Abstract:
Objective To investigate the status and molecular epidemiology of hepatitis D virus (HDV) infection in the gathering area of Mongolian population in Inner Mongolia Autonomous Region of China. Methods A total of 230 patients with positive hepatitis B surface antigen (HBsAg) who attended Inner Mongoli...

Original Article_Fatty Liver Disease

Influencing factors for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus

Shunxiao ZHANG, Sheng ZHANG, Yan ZHANG, Yuanyuan LI, Yue CHEN, Mingyu SUN

2023, 39(5): 1081-1088. DOI: 10.3969/j.issn.1001-5256.2023.05.013

Abstract(523)

HTML (187)

PDF (2079KB)(78)

Abstract:
Objective To investigate related influencing factors in patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Methods A total of 252 patients with T2DM who were treated in Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine from May ...

Original Article_Liver Fibrosis and Liver Cirrhosis

Establishment and evaluation of a multivariate Cox proportional-hazards prediction model for mortality during short-term hospitalization in patients with liver cirrhosis and sepsis

Linlin XUE, Binghan LI, Chunyun LIU, Weikun LI, Lixian CHANG, Li LIU

2023, 39(5): 1089-1097. DOI: 10.3969/j.issn.1001-5256.2023.05.014

Abstract(460)

HTML (123)

PDF (2199KB)(68)

Abstract:
Objective To establish a Cox proportional-hazards prediction model for mortality during short-term hospitalization in patients with liver cirrhosis and sepsis. Methods A retrospective analysis was performed for the clinical data of 336 patients with liver cirrhosis and sepsis who were admitted to Th...

Original Article_Other Liver Disease

Value of Charlson comorbidity index in predicting the prognosis of patients with acute-on-chronic liver failure

Fuchun WANG, Wanjie ZHANG, Ziyi LI, Yongwu MAO, Aiping TIAN, Xiaorong MAO, Junfeng LI

2023, 39(5): 1098-1104. DOI: 10.3969/j.issn.1001-5256.2023.05.015

Abstract(673)

HTML (229)

PDF (2205KB)(68)

Abstract:
Objective To investigate the value of Charlson comorbidity index (CCI) in predicting the short- and long-term risks of death in patients with acute-on-chronic liver failure (ACLF). Methods A total of 317 patients with ACLF who attended The First Hospital of Lanzhou University from December 1, 2016 t...

Etiological spectrum and clinical features of patients with unexplained liver disease manifesting as isolated jaundice: An analysis of 91 cases

Yufeng ZHENG, Xulei ZHANG, Yuhang WENG, Yongfeng YANG

2023, 39(5): 1105-1109. DOI: 10.3969/j.issn.1001-5256.2023.05.016

Abstract(606)

HTML (131)

PDF (1926KB)(84)

Abstract:
Objective To investigate the etiological and clinical features of patients with unexplained liver disease manifesting as isolated jaundice and the value of whole-exome sequencing in the diagnosis of such diseases. Methods A retrospective analysis was performed for the clinical data of the patients w...

Effect of Toll-like receptor 4 on liver regeneration during acetaminophen-induced liver injury in mice

Mingyue CHEN, Xiuliang ZHENG, Yaqin QIAO, Haitao SHEN, Yan LU

2023, 39(5): 1110-1118. DOI: 10.3969/j.issn.1001-5256.2023.05.017

Abstract(676)

HTML (108)

PDF (4566KB)(73)

Abstract:
Objective To investigate whether Toll-like receptor 4 (TLR4) inhibition affects liver regeneration during acetaminophen (APAP)-induced liver injury in mice, as well as the mechanism of TLR4 involved in liver regeneration. Methods A total of 78 male CD-1 mice were divided into nine groups using a ran...

Mechanism of action of Dange Jiecheng decoction in a rat model of alcoholic liver disease based on the Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling pathway

Ming WANG, Jianhu XU, Li MA

2023, 39(5): 1119-1125. DOI: 10.3969/j.issn.1001-5256.2023.05.018

Abstract(499)

HTML (159)

PDF (2919KB)(61)

Abstract:
Objective To investigate the therapeutic effect of Dange Jiecheng decoction on a rat model of alcoholic liver disease (ALD) and the anti-oxidative stress mechanism of Dange Jiecheng decoction. Methods A total of 96 Sprague-Dawley rats were randomly divided into blank group with 13 rats and ALD group...

Original Article_Biliary Disease

Effect of Yinchenhao decoction on renal oxidative stress injury in rats with obstructive jaundice and its mechanism of action based on the nuclear factor erythroid 2-related factor 2 signaling pathway

Junjian LIU, Shuai CHEN, Hongxia YUAN, Yan XU, Xibo ZHANG, Zhonglian LI

2023, 39(5): 1126-1133. DOI: 10.3969/j.issn.1001-5256.2023.05.019

Abstract(574)

HTML (110)

PDF (2889KB)(46)

Abstract:
Objective To investigate the effect of Yinchenhao decoction on renal oxidative stress injury in rats with obstructive jaundice and its association with the regulation of the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and nuclear translocation. Methods A total of 32 male Sprague...

Original Article_Pancreatic Disease

Role of the Sonic Hedgehog signaling pathway in intestinal mucosal barrier injury in rats with severe acute pancreatitis

Lin WEN, Jiayue ZENG, Fengyu MA, Xia CHEN

2023, 39(5): 1134-1143. DOI: 10.3969/j.issn.1001-5256.2023.05.020

Abstract(739)

HTML (242)

PDF (5731KB)(52)

Abstract:
Objective To investigate the expression and role of the Sonic Hedgehog (Shh) signaling pathway in intestinal mucosal barrier injury in rats with severe acute pancreatitis (SAP). Methods A total of 48 Sprague-Dawley rats were divided into sham-operation group (Sham group), SAP model group (SAP group)...

Brief Report

Histopathological characteristics of the liver in children with non-alcoholic fatty liver disease

Min LIU, Weijian CHEN, Zhengzhen ZHOU, Xiaomei QIN, Rong WEN, Nan JIANG, Linzhi KUANG, Taiqing ZHENG, Liqiong ZHANG, Shuangjie LI

2023, 39(5): 1144-1149. DOI: 10.3969/j.issn.1001-5256.2023.05.021

Abstract(432)

HTML (140)

PDF (3065KB)(53)

Abstract:

Case Report

Autoimmune hepatitis-primary biliary cholangitis overlap syndrome with gastric adenocarcinoma: A case report

Lichen LI, Shaohui TANG

2023, 39(5): 1150-1153. DOI: 10.3969/j.issn.1001-5256.2023.05.022

Abstract(423)

HTML (159)

PDF (2317KB)(62)

Abstract:

A case of atypical hepatic hemangioma misdiagnosed as hepatic cystadenoma

Sha WANG, Yanli ZHANG, Yuanyuan CHEN, Qinqin MA, Junqiang LEI

2023, 39(5): 1154-1156. DOI: 10.3969/j.issn.1001-5256.2023.05.023

Abstract(471)

HTML (81)

PDF (2557KB)(52)

Abstract:

Endoscopic retrograde cholangiopancreatography combined with peroral choledochoscopy in treatment of common bile duct stones with gallbladder neck stones and gallbladder polyps: A case report

Liying TAO, Hongguang WANG, Qingmei GUO, Yingting DU, Lianyu PIAO, Jing LIU, Feng JIANG

2023, 39(5): 1157-1161. DOI: 10.3969/j.issn.1001-5256.2023.05.024

Abstract(828)

HTML (286)

PDF (2850KB)(63)

Abstract:

Mucinous gallbladder adenoma diagnosed by endoscopic retrograde cholangiopancreatography and SpyGlass: A case report

Xinyu LU, Linheng WANG, Gui JIANG, Yifei YUN, Shuo HUANG, Lijie ZHANG

2023, 39(5): 1162-1165. DOI: 10.3969/j.issn.1001-5256.2023.05.025

Abstract(389)

HTML (172)

PDF (2680KB)(40)

Abstract:

Review

Association between bile acids and nonalcoholic fatty liver disease

Junjun WANG, Xiaobo CAI, Lungen LU

2023, 39(5): 1166-1171. DOI: 10.3969/j.issn.1001-5256.2023.05.026

Abstract(751)

HTML (290)

PDF (1878KB)(201)

Abstract:
With the rapid increase in the prevalence rate of nonalcoholic fatty liver disease (NAFLD), new treatment methods are needed to prevent disease progression to liver fibrosis, liver cirrhosis, and liver cancer. Although great efforts have been made to clarify the pathological mechanisms of NAFLD dise...

Role of bone morphogenetic protein-4 in the pathogenesis of nonalcoholic fatty liver disease

Yuwei WANG, Jinchun LIU, Ru CHAI

2023, 39(5): 1172-1177. DOI: 10.3969/j.issn.1001-5256.2023.05.027

Abstract(462)

HTML (98)

PDF (2189KB)(36)

Abstract:
Nonalcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases in the world, and it seriously harms human health. Recent studies have found that bone morphogenetic protein 4 (BMP4) might be associated with NAFLD. This article reviews the latest advances in the rese...

Advances in the application of nonselective β-receptor blockers in treatment of liver cirrhosis

Yifeng LIU, Xiaoze WANG, Li YANG

2023, 39(5): 1178-1183. DOI: 10.3969/j.issn.1001-5256.2023.05.028

Abstract(696)

HTML (387)

PDF (1883KB)(125)

Abstract:
Nonselective β-receptor blockers (NSBBs) are first-line drugs for the prevention and treatment of complications in cirrhotic patients with portal hypertension and are widely used in the primary and secondary prevention of esophagogastric variceal bleeding. In recent years, studies have shown that in...

Current research status of spleen stiffness measurement in predicting portal hypertension and its complications in patients with liver cirrhosis

Jiqing LIU, Fankun MENG, Huiguo DING, Jianjun LI, Qun HUANG, Hongmei ZU, Jing ZHANG

2023, 39(5): 1184-1190. DOI: 10.3969/j.issn.1001-5256.2023.05.029

Abstract(823)

HTML (192)

PDF (1892KB)(127)

Abstract:
Liver stiffness measurement (LSM) has been widely used in predicting portal hypertension in clinical practice, and in recent years, spleen stiffness measurement (SSM) has also become a diagnostic tool. Studies have shown that SSM can predict portal hypertension and its complications such as esophago...

Current research status of prognostic models for transjugular intrahepatic portosystemic shunt

Hui LI, Zhibo XIA, Nianjun XIAO, Jianguo CHU, Shoubin NING, Zheyi HAN

2023, 39(5): 1191-1196. DOI: 10.3969/j.issn.1001-5256.2023.05.030

Abstract(458)

HTML (190)

PDF (1876KB)(48)

Abstract:
Transjugular intrahepatic portosystemic shunt (TIPS) is a safe and effective method for the treatment of portal hypertension complications in patients with decompensated liver cirrhosis. At present, there are many prognostic scoring tools for risk stratification of poor prognosis after TIPS. This ar...

Research advances in immunotherapy for hepatocellular carcinoma

Lizhen ZHU, Xiaolei XU, ABUDUSALAMU Aini, Xiaojuan WANG, Hu ZHOU, Rui TANG, Haining FAN, Qian LU

2023, 39(5): 1197-1203. DOI: 10.3969/j.issn.1001-5256.2023.05.031

Abstract(1067)

HTML (193)

PDF (1884KB)(201)

Abstract:
Hepatocellular carcinoma (HCC) has an insidious onset, and most patients are in the advanced stage when attending the hospital and thus lose the opportunity for radical surgical resection, which results in the poor prognosis of patients. With the development of clinical treatment, the treatment of a...

Role of macrophage polarization and its crosstalk with neighboring cells in hepatocellular carcinoma

Huiji SU, Gengjie YAN, Hanxiao CHEN, Shaoqun BAN, Ailing WEI, Dewen MAO, Fuli LONG

2023, 39(5): 1204-1211. DOI: 10.3969/j.issn.1001-5256.2023.05.032

Abstract(887)

HTML (749)

PDF (2693KB)(86)

Abstract:
Inflammation is closely associated with the development of cancer. Tumor-associated macrophages (TAM) actively participate in tumor-related inflammation and promote tumor growth and metastasis, while under certain conditions, TAM also show cytotoxicity and tumor killing activity and thus inhibit the...

Research advances in tumor-associated macrophages in hepatocellular carcinoma microenvironment

Peng WANG, Jiannan QIU, Zhongxia WANG, Junhua WU, Chunping JIANG

2023, 39(5): 1212-1218. DOI: 10.3969/j.issn.1001-5256.2023.05.033

Abstract(722)

HTML (183)

PDF (1890KB)(79)

Abstract:
Since there is a lack of obvious clinical symptoms in the early stage of hepatocellular carcinoma (HCC), most patients have progressed to the advanced stage at the time of confirmed diagnosis. There are limited treatment options for HCC patients who miss the opportunity for surgery, so it is of grea...

Methods for evaluating liver reserve function before hepatectomy

Junpeng PEI, Youming DING

2023, 39(5): 1219-1226. DOI: 10.3969/j.issn.1001-5256.2023.05.034

Abstract(822)

HTML (190)

PDF (1908KB)(160)

Abstract:
At present, hepatectomy has become the preferred treatment modality for most benign and malignant hepatobiliary diseases. Liver failure is a common complication after hepatectomy, and for malignant diseases, how to remove the lesion to the maximum extent and reduce the incidence rate of liver failur...

Research advances in acute pancreatitis-associated ascites fluid

Zhangpeng WANG, Jun WU, Guangxu JING, Xuyang WANG, Hong ZOU, Hongyu SUN, Lijun TANG

2023, 39(5): 1227-1233. DOI: 10.3969/j.issn.1001-5256.2023.05.035

Abstract(620)

HTML (86)

PDF (1890KB)(85)

Abstract:
Acute pancreatitis-associated ascites fluid (PAAF) is a common complication in patients with acute pancreatitis (AP) and is closely associated with the severity of AP, the development of local and systemic complications, and prognosis. PAAF may originate from the leakage of abdominal blood vessels, ...

Role of thymoquinone in treatment of pancreatic cancer

Zhanxue ZHAO, Linxun LIU, Shuai LI, Xiaofan HOU, Jinyu YANG

2023, 39(5): 1234-1244. DOI: 10.3969/j.issn.1001-5256.2023.05.036

Abstract(739)

HTML (424)

PDF (3990KB)(53)

Abstract:
Pancreatic cancer is one of the cancers with the worst prognosis, and its high metastasis rate and resistance to chemotherapy drugs have always been the tough problems in the medical field. At present, the effect of thymoquinone on pancreatic cancer has attracted wide attention, and it can exert an ...